Guardian Pharmacy Services Reports Strong Q4 and FY2024 Results; Provides 2025 Guidance

Guardian Pharmacy Services, Inc. (NYSE: GRDN), a leading long-term care (LTC) pharmacy services company, has announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. The company reported strong performance, driven by organic growth, strategic acquisitions, and seasonal vaccination services. Guardian will discuss these results and provide guidance during a presentation at the Raymond James & Associates 46th Annual Institutional Investors Conference on March 12, 2025.

Fourth Quarter and Full Year Selected Preliminary Unaudited Financial Information

| Metric | Q4 2024 | Full Year 2024 | Initial 2025 Full Year Guidance |
| --- | --- | --- | --- |
| Revenue | $338.6 million | $1.228 billion | $1.330-1.350 billion |
| Revenue Growth (YoY) | 20.5% | 17.4% | 8.3-9.9% |
| Resident Count | 186,000 | 180,000 | N/A |
| Resident Count Growth (YoY) | 14.1% | 12.0% | N/A |
| Adjusted EBITDA | $23.0 million | $90.8 million | $97.0-101.0 million |
| Adjusted EBITDA Growth (YoY) | 30.3% | 19.2% | 6.8-11.2% |
| Net Income (Loss) | $10.1-11.1 million | ($71.8-72.8 million) | N/A |
| Net Income Growth (YoY) | N/A | N/A | N/A |

Guardian Pharmacy Services' preliminary results reveal significant growth in Q4 2024, with revenue increasing by 20.5% year-over-year to $338.6 million. The company's resident count grew by 14.1% year-over-year to 186,000. The spread between revenue growth and resident count growth indicates higher revenue per resident, likely from expanded services and vaccination programs. For full-year 2024, Guardian expects revenue of $1.228 billion, a 17.4% increase year-over-year, but projects a net loss between $71.8-72.8 million, primarily due to share-based compensation related to their corporate reorganization and IPO.

For 2025, Guardian projects revenue of $1.330-1.350 billion and Adjusted EBITDA of $97.0-101.0 million, representing growth of 8.3-9.9% and 6.8-11.2% respectively. The stronger Q4 adjusted EBITDA growth compared to revenue growth demonstrates improving operational leverage and efficiency as scale increases.

Guardian Pharmacy Services' strong performance in Q4 2024 and full-year 2024 is a testament to the company's strategic focus on organic growth, acquisitions, and expanded services, including seasonal vaccination programs. The company's ability to adapt to market demands and optimize its operations has positioned it well for continued growth in 2025. Investors should closely monitor Guardian's progress as it continues to execute on its growth strategy and provide updates on its financial performance.